ITOS - Roche send anti-TIGIT developers higher after mistakenly released cancer drug data
2023-08-23 07:31:22 ET
More on Roche
-
Roche drives rival anti-TIGIT developers higher after cancer drug data
-
Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender
- Roche, Alnylam in pact for blood pressure candidate
- Roivant reportedly could sell colitis drug to Roche for over $7B
- Roche pulls thyroid cancer indication for Gavreto
- Roche withdraws filing for eye implant Susvimo for wet AMD in EU
For further details see:
Roche send anti-TIGIT developers higher after mistakenly released cancer drug data